Physician profile
Lance Lee Bechtold
NPI 1336554070
$3,991.88
in general payments reported to CMS, 2019-2025
28 companies · $1,186 in 2025
The $1,186 reported for 2025 was more than what 82% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $82.18 · 2020: $225 · 2021: $554 · 2022: $486 · 2023: $688 · 2024: $772 · 2025: $1,186.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,567 · Education: $77.91.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,567.21 |
| Education | $77.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $832.23 | 2019-2025 | Farxiga, Lokelma |
| Amgen INC. | $591.50 | 2022-2025 | Krystexxa, Tavneos |
| Otsuka America Pharmaceutical, INC. | $430.72 | 2021-2025 | Jynarque, Voyxact |
| Bayer Healthcare Pharmaceuticals INC. | $385.17 | 2021-2025 | |
| Horizon Therapeutics Plc | $251.46 | 2021-2023 | Krystexxa |
| Opko Pharmaceuticals, LLC | $204.49 | 2019-2024 | Rayaldee |
| Akebia Therapeutics INC | $154.15 | 2019-2025 | Vafseo |
| Vifor Pharma, INC. | $141.50 | 2020-2023 | Veltassa, Korsuva |
| Daiichi Sankyo INC. | $131.10 | 2023-2025 | Injectafer |
| Mallinckrodt Hospital Products INC. | $129.11 | 2023-2025 | Acthar |
| Calliditas Therapeutics US INC. | $104.02 | 2023-2025 | Tarpeyo |
| Shield Therapeutics INC | $75.03 | 2025 | |
| Renalytix Ai, INC. | $74.63 | 2025 | Kidneyintelx Blood Collection Convenience Kit |
| Travere Therapeutics, INC. | $73.43 | 2023-2025 | Filspari |
| Aurinia Pharma U.S., INC. | $65.24 | 2022-2025 | Lupkynis |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $59.13 | 2024-2025 | Ibsrela |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $44.74 | 2025 | |
| Novo Nordisk INC | $35.62 | 2021-2023 | Ozempic |
| Glaxosmithkline, LLC. | $32.93 | 2020-2024 | Jesduvroq, Benlysta |
| Alexion Pharmaceuticals, INC. | $32.18 | 2020-2023 | Ultomiris |
| Abbott Laboratories | $23.29 | 2023 | Cardiomems |
| Xeris Pharmaceuticals, INC. | $20.94 | 2022 | |
| Boston Scientific Corporation | $19.79 | 2023 | |
| Fresenius USA Marketing, INC. | $19.12 | 2019 | |
| Lilly USA, LLC | $18.88 | 2025 | Jardiance |
| Leadiant Biosciences, INC. | $16.91 | 2022 | |
| Inspire Medical Systems, INC. | $13.53 | 2025 | Inspire |
| Ultragenyx Pharmaceutical INC. | $11.04 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lance Bechtold listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.